Compare NEOG & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | PVLA |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1995 | 2013 |
| Metric | NEOG | PVLA |
|---|---|---|
| Price | $11.87 | $128.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $14.00 | ★ $230.53 |
| AVG Volume (30 Days) | ★ 3.9M | 164.9K |
| Earning Date | 10-06-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.20 | 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $870,400,000.00 | $42,810,000.00 |
| Revenue This Year | $1.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $5.37 | $65.93 |
| 52 Week High | $14.26 | $161.38 |
| Indicator | NEOG | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 31.09 |
| Support Level | $8.68 | $109.68 |
| Resistance Level | $12.55 | $135.23 |
| Average True Range (ATR) | 0.71 | 6.38 |
| MACD | -0.16 | -2.30 |
| Stochastic Oscillator | 1.90 | 14.11 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.